The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …

Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …

Abstract Introduction and Objectives Novel oral anticoagulants are emerging options for the
prevention and treatment of thromboembolic diseases. They are increasingly used in clinical …

Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …

Objective: The aim of this study was to evaluate, from the Spanish National Health System
perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol …

Approximately 250,000 Canadians are affected by atrial fibrillation (AF). Stroke is a
complication of AF, and Canadians with AF are five times more likely to have a stroke and …

Aims We assessed the effect of concomitant aspirin use on the efficacy and safety of
apixaban compared with warfarin in patients with atrial fibrillation (AF). Methods and results …

Objective To compare real-world effectiveness and safety of direct oral anticoagulants
(DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke. Study …